GSK plc
Researches, develops and manufactures vaccines, specialty medicines and general medicines for disease prevention and treatment globally, with particular focus on oncology, respiratory conditions and immunology.
As of Jul 17, 2026
Executive summary
GSK plc is a London-listed pharmaceutical and healthcare company with a market capitalisation of £78.3 billion. The stock is trading at 1,917p and shows a bearish technical bias, having fallen 2.0 percent today, though it remains up 47.5 percent over the past year. The one-month return of -0.3 percent signals recent weakness despite the longer-term gains.
Price history
As of Jul 17, 2026
Performance
-2.02%
-2.29%
-0.34%
-9.80%
+6.85%
+47.54%
As of Jul 17, 2026
Technical indicators
- 44.3
- -7.95Bearish
- 50: 1926.57 · 200: 1892.18
- 1,930p / 2,049p
Technical Bias
Bearish lean
GSK plc is trading at 1,917p with a derived technical read skewed bearish. The MACD sits at −7.95 (bearish signal), while RSI at 44.3 and moving averages (50-day at 1,926.57p, 200-day at 1,892.18p) remain neutral, giving a tally of one bearish, two neutral signals. This is a technical read, not investment advice.
A transparent read of the indicators below — not a prediction or recommendation.
As of Jul 17, 2026
Fundamentals
- £78.3B
- 13.77
- 1.42p
- 17.78%
- +1.5%
- £5.96B
- 0.3
- 1,256p – 2,245p
- 3.55%
- May 14, 2026
- —
As of Jul 17, 2026
Latest news
As of Jul 17, 2026
Short-term outlook
GSK shares have been largely rangebound over the past month, down just 0.3%, with the MACD leaning bearish while RSI sits neutral at 44.3, suggesting no strong momentum either way. With price sitting close to the 1,930p support level and the 50- and 200-day averages bunched together, the next few weeks could hinge on whether that floor holds or gives way towards 2,049p resistance.
Medium-term outlook
GSK trades on a modest 13.77 price-to-earnings ratio, with revenue growth of just 1.5% year-on-year suggesting a slow-growing business, though a healthy 17.8% profit margin and a 3.5% dividend yield offer some support for income-focused holders. With the technical picture leaning bearish, the next few quarters may test whether steady fundamentals can offset weaker price momentum.
Key risks
- Revenue growth of just +1.5% year on year is modest, and the market will be watching closely to see whether the incoming chief executive's strategy update can reaccelerate it.
- The Nuvalent tender offer at $124 per share adds acquisition and integration risk, along with the usual uncertainty around whether a deal of this size completes on the proposed terms.
- UBS's neutral stance suggests the market isn't yet convinced on direction, and with the stock trading well below its 52-week high of 2,245p, sentiment could stay cautious until there's more clarity.
- As a pharmaceutical business, GSK remains exposed to regulatory and approval risk across its pipeline, so newer wins like Utebzi and momelotinib's orphan tag still need to translate into commercial results.
About GSK plc
GSK plc is a UK-based healthcare company listed on the London Stock Exchange under the ticker GSK. Operating in the drug manufacturing space, it sits among the larger names in the sector, with a market capitalisation of £78.3 billion reflecting its scale and standing within global pharmaceuticals. As a major manufacturer, GSK's business spans the kind of broad drug development and production work typical of established healthcare industry leaders.
Looking at the key figures, GSK trades on a price-to-earnings ratio of 13.77, giving a sense of how the market is currently valuing its earnings relative to peers. The dividend yield stands at +3.5%, a figure income-focused investors often watch closely. Together, these metrics offer a snapshot of how the market currently views GSK's earnings profile and its approach to shareholder returns.
AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk.